| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLK2 |
| Uniprot No | P49760 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 138-499aa |
| 氨基酸序列 | RRAKSVEDDAEGHLIYHVGDWLQERYEIVSTLGEGTFGRVVQCVDHRRGGARVALKIIKNVEKYKEAARLEINVLEKINEKDPDNKNLCVQMFDWFDYHGHMCISFELLGLSTFDFLKDNNYLPYPIHQVRHMAFQLCQAVKFLHDNKLTHTDLKPENILFVNSDYELTYNLEKKRDERSVKSTAVRVVDFGSATFDHEHHSTIVSTRHYRAPEVILELGWSQPCDVWSIGCIIFEYYVGFTLFQTHDNREHLAMMERILGPIPSRMIRKTRKQKYFYRGRLDWDENTSAGRYVRENCKPLRRYLTSEAEEHHQLFDLIESMLEYEPAKRLTLGEALQHPFFARLRAEPPNKLWDSSRDISR |
| 预测分子量 | 58.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLK2重组蛋白的3篇参考文献摘要：
---
1. **文献名称**: *"CDC-like kinase 2 (CLK2) phosphorylates tau and promotes neurodegeneration"*
**作者**: Smith A, et al.
**摘要**: 研究报道了重组CLK2蛋白在体外直接磷酸化tau蛋白的机制，揭示了其通过调控tau病理促进阿尔茨海默病神经退行性变的潜在作用。
---
2. **文献名称**: *"CLK2 regulates DNA damage response and cancer cell survival via p53 phosphorylation"*
**作者**: Lee J, et al.
**摘要**: 利用重组CLK2蛋白进行体外激酶实验，发现其通过磷酸化p53蛋白调控DNA损伤修复通路，影响乳腺癌细胞的凋亡抵抗和化疗敏感性。
---
3. **文献名称**: *"Structural and functional characterization of recombinant human CLK2 kinase"*
**作者**: Zhang Y, et al.
**摘要**: 该研究通过重组表达纯化人源CLK2蛋白，解析其晶体结构并分析激酶活性，为靶向CLK2的药物开发提供了结构基础。
---
注：以上文献为示例，实际引用需核实具体论文信息。建议通过PubMed或Web of Science以“CLK2 recombinant protein”为关键词检索最新研究。
CLK2 (CDC-like kinase 2) is a serine/threonine protein kinase belonging to the CLK (CDC2-like kinase) family, which plays a critical role in regulating pre-mRNA splicing through phosphorylation of SR (serine/arginine-rich) proteins. These splicing factors are essential for spliceosome assembly and alternative splicing, impacting gene expression diversity. CLK2 is involved in multiple cellular processes, including cell cycle control, stress response, and metabolic regulation. Dysregulation of CLK2 has been linked to neurodegenerative diseases, cancer, and metabolic disorders, making it a potential therapeutic target.
Recombinant CLK2 protein is engineered using genetic engineering techniques, typically expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian or insect cells) to ensure proper post-translational modifications and kinase activity. The purified protein retains enzymatic functionality and is widely used in biochemical assays, drug discovery, and mechanistic studies. Researchers employ recombinant CLK2 to screen kinase inhibitors, study phosphorylation-dependent signaling pathways, or explore its interaction with substrates like SRSF proteins. Structural studies using recombinant CLK2 have also revealed ATP-binding pocket features, guiding the design of selective inhibitors.
Its relevance in disease contexts—such as Alzheimer’s (linked to tau phosphorylation) and cancers (aberrant splicing)—has spurred interest in CLK2-targeted therapies. Recombinant CLK2 tools enable high-throughput screening for compounds modulating its activity, offering pathways to novel treatments. Quality control measures, including kinase activity assays and mass spectrometry, ensure batch consistency for research and preclinical applications.
×
